Abstract library

7 results for "Bongiovanni".
#1102 First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis
Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Alberto Bongiovanni
Keywords: GEP-NEC, chemotherapy
#1128 FDG PET as a Prognostic Factor in Pancreatic Neuroendocrine Tumors (P-NET) After Peptide Receptor Radionuclide Therapy with 177Lu-dotatate (Lu-PRRT).
Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
#1277 Long-term Follow up of Peptide Receptor Radionuclide Therapy with 177Lu-dotatate in Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
Introduction: 177Lu-dotatate(Lu-PRRT) is a valid therapeutic option in advanced G1-G2 pancreatic neuroendocrine tumors (P-NETs)
Conference: 13th Annual ENETS conference 2016 (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: MD Maddalena Sansovini
Keywords: PRRT, FDG-PET, P-NET
#1578 Everolimus Cumulative Dose and Dose Intensity in Pancreatic Neuroendocrine Tumors
Introduction: Everolimus represents a new treatment option for advanced pancreatic neuroendocrine tumors (pNETs).
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Prof. Rossana Berardi
#1871 Sunitinib (Su) in Progressive Pancreatic Neuroendocrine Tumor (PNET) Administered in Different Treatment Lines
Introduction: Su has shown PFS improvement in patients (pt) with PNET in phase III trial
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Riccardo Marconcini
Keywords: sunitinib
#3016 DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance
Introduction: The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: PhD Chiara Liverani
#3025 Phase-II Trials of Pazopanib in Metastatic Neuroendocrine Neoplasia (NEN): A Systematic Review and Meta-Analysis
Introduction: Several Phase-II trials have been designed to evaluate Tyrosine Kinase Inhibitor (TKI) and in particular Pazopanib in Neuroendocrine Neoplasia (NEN) but it’s efficacy is not yet demonstrated in a randomized Phase III trial.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr. Alberto Bongiovanni